ABSTRACT
INTRODUCTION
The severity and course of acute pancreatitis (AP) are difficult to evaluate by assessing the first symptoms and clinical signs alone. Although it is mostly self-limiting, approximately 20-30% of all patients will progress to a severe form, which has approximately a 5% mortality rate [1, 2] . An early prediction of AP severity is important in the evaluation of the clinical prognosis and treatment. In a clinical setting, various methods have been used to predict AP severity, including the Acute Physiology and Chronic Health Evaluation (APACHE) II score, Ranson score, and CRP after the first 24 h [3] [4] . Recent studies have shown that CD64 index was correlated with disease severity in SAP and may act as a useful marker for the prediction of the development of SAP [5] [6] . The expression of HLA-DR on monocytes was highly related to the effector functions of the monocytes. CD14 + HLA-DR low/-cells, the myeloid-derived suppressor cells with immunosuppressive lymphocyte function, have also been shown to predict the development of organ failure and a fatal outcome [7] . However, these methods in the prediction of AP severity have limitations in the clinical practice. Research has thus focused on the search for novel biochemical markers that can predict AP severity in the initial 24 h following admission.
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At present, it is widely accepted that AP is an inflammatory disorder. As an inflammatory process, AP results in excessive leukocyte activation and increased migration of neutrophils to the inflamed area, with a consequent release of pro-inflammatory mediators including interleukins (IL-6, IL-8, IL-15, IL-33, and IL-17), procalcitonin and tumor necrosis factor-a (TNF-α) [8] [9] [10] [11] [12] [13] . To maintain immune homeostasis, the body contains regulatory cells which secrete anti-inflammatory factors (e.g., IL-10, transforming growth factor β (TGF-β)) to limit the inflammation process [14] . Normally, the proand anti-inflammatory responses are maintained in a state of balance. In SAP, however, this balance is disrupted, and an abnormal activation of inflammatory cells leads to systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction (MODS).
Studies have shown that T helper cells play critical roles in the pathogenesis of AP [15, 16] , but the role of regulatory B cells remains unclear. Regulatory B cells are potent negative regulators of inflammation and autoimmune diseases via the release of IL-10 or TGF-β. B10 cells are now recognized as an important component of the immune system. Two B subsets including memory CD19 + CD24 hi CD27 hi [17] and immature/transitional CD19 + CD24 hi CD38 hi B cells [18] , both of which can secrete IL-10 in vitro depending on various stimulations, have been identified in humans. Human CD19 + CD24 hi CD38 hi cells have been reported to suppress Th1 and Th17 cell differentiation through the production of IL-10 [19] . Carter NA found that, in humans, under conditions of pan-B cell depletion, including regulatory B cell depletion, the inflammatory response will be uncontrolled [20] . The aim of this study was to assess circulating B10 and memory CD19 + CD24 hi
CD27
hi cells among patients with AP of varying severity at the early phase of the disease (first 48 h from the onset of abdominal pain) and to evaluate their diagnostic utility for the prediction of AP severity. The numbers of leukocytes were significantly higher but the numbers of lymphocytes were significantly lower in patients with AP on admission than those of healthy individuals (all P < 0.001), but no significant difference in the numbers of leukocytes and lymphocytes was observed between patients with MAP and SAP (P = 0.0945, P = 0.0514, respectively, Table 1 
RESULTS

Decreased
CD27
hi cells in patients with SAP were significantly lower than those in patients with MAP (P = 0.0198, P = 0.0028, P = 0.0313, respectively, Figure 1A-1J 
hi cells in patients with MAP and SAP was detected compared with that in healthy individuals (all P < 0.001, Figure 2A , 2C, 2D, 2F, 2G, 2I, 2J, 2L); Similarly, the MFI of CD80 and CD86 on B10 or CD19
hi cells in patients with SAP was lower than that in patients with MAP (P = 0.029, P = 0.0067, P = 0.028, P < 0.001). However, the frequencies of CD80 and CD86 on B10 or CD19
hi cells were not different between patients with AP and healthy individuals ( Figure 2B , 2E, 2H, 2K 
CD25
+ T cells alone ( Figure 3D ). We also analyzed the production of IL-10 and TGF-β on CD4 Figure  5A -5E). Interestingly, when we compared MAP patients with healthy individuals, the frequencies and numbers of CD14 + HLA-DR low/-cells and CD64 index also differed significantly between the 2 groups (P < 0.001, P < 0.001, P = 0.0034).
Serum cytokines except for IFN-γ are increased in patients with AP
We know that cytokines play a crucial role in the pathogenesis of AP as they drive the additional inflammatory response, which leads to tissue damages and organ dysfunction. As previously reported [21] , our results showed that the serum levels of IL-6, IL-10, IL-17, TNF-α and TGF-β were all increased in patients with MAP and SAP compared with the corresponding levels in healthy individuals (all P < 0.001, Figure 6A -6C, E ,F); these levels were actually increased along with AP severity, and a significant difference was observed between patients with MAP and SAP (all P < 0.05). However, the IFN-γ levels in AP patients were not different from the levels in healthy individuals ( Figure 6D ). The time course of the change in cytokine levels of six patients with MAP and SAP is shown in Figure 6G -6L. In patients with MAP, the levels of IL-6, IL-10, IL-17, TNF-α and TGF-β decreased from day 1 to day 7 ( Figure 6K ). In patients with SAP, the levels of all the studied cytokines remained stable except for the levels of IFN-γ which increased over time ( Figure 6J ). Figure 7A, 7B, 7D, 7F, 7G, 7H ).
Dynamic longitudinal observation of B10 or CD19
inflammatory markers during the progression of AP, we analyzed six patients with MAP and six patients with SAP from day 1
CD19
+ and Th1 cells remained stable over time in both groups ( Figure 7C, 7F ). 
B10 and CD19
DISCUSSION
Early stratification of AP severity, especially severe cases, is clinically important for the determination of optimal or intensive treatment to improve outcomes [22] . Clinical scoring systems (APACHE II score and Ranson score) and several serum markers (CRP, procalcitonin, IL-6, and IL-8) have been used to assess the severity of AP [23] [24] . However, these approaches have limitations. Conventional severity scores consist of multiple factors (Ranson, 11 factors; and APACHE II, 14 factors) and are complicated, and they may therefore be difficult to accomplish in clinical practice when patients are admitted and TGF-β (L) from patients with MAP (n = 6) and SAP (n = 6).
* P < 0.05, ** P < 0.01. www.oncotarget.com to a hospital. Taken together, novelpathogenically relevant biomarkers for the early prediction of disease severity are needed.
Immunologic impairment in the early phase of AP may be linked to an increased susceptibility to subsequent infection and the development of septic complications. The phenomenon of immunoparalysis, defined as downregulation of HLA-DR expression on monocytes, and disequilibrium of various helper T cell subsets are usually associated with exaggerated anti-inflammatory responses and high bacterial complications in patients with sepsis, burns, cirrhosis, or AP [14, 15, 25] . These results indicate that immune cells are involved in the pathophysiological process and determine the severity of AP. Regulatory B cells, which are increased in human inflammatory and autoimmune diseases, were previously ascribed with the capacity to suppress autoimmune inflammation, chronic T cell inflammation, and possibly antitumor immunity [26, 27] . Regulatory B cells suppress immune responses via the release of IL-10 or TGF-β, the inhibition of the release of IFN-γ and TNF-α and the induction of Tregs populations as well as interaction with target cells via molecules expressed on the cell surface, such as CD80, CD86 [18, [26] [27] [28] [29] [30] . But our study showed a significant reduction in lymphocytes, CD19 
CD27
hi cells may be important contributors to immune dysfunction in AP and may be associated with the degree of organ failure and high mortality in patients with SAP.
It is now established that B lymphocytes contribute directly to enhanced T cell activation and differentiation (e.g., Th1 and Th17) via the production of proinflammatory cytokines (such as IL-6 and TNF-α) [32] . Th17 cells and related cytokines (IL-6, IL-17) have been used to assess severity in studies of AP [10, 15, [33] [34] [35] . IL-17 promotes the differentiation of B cells into antibody-secreting plasma cells in autoimmune diseases [36] . TNF-α, which is released by many immune cells low/-monocytes, is associated with a more severe course of AP, including SIRS and MODS [37] . Just as IL-17 and IL-6 contribute to the differentiation of Th17 cells, IL-10 and TGF-β contribute to the differentiation of regulatory cells [17, 18, 27] . In response to certain stimuli, any B cell could potentially differentiate into a ''regulatory B cell,'' which can then suppress local inflammation [38] . In our study, serum IL-6, IL-10, IL-17, TNF-α and TGF-β levels were increased in patients with AP at admission and were then decreased on day 7 in patients with MAP, whereas the levels remained stable, with the exception of IFN-γ, in patients with SAP. hi cells reflected the general inflammatory response and predicted the AP severity. However, the identity of the specific cytokines that inhibit the development of B10 and CD19
hi cells requires further study.
To assess the diagnostic value of B10 and CD19
hi cells, we compared the numbers of B10 and CD19
hi cells on day 3 with APACHE II score, CRP, CD64 index and cytokines. Our previous report showed that CD64 index and CD14 + HLA-DR low/-cells were increased in patients with AP and were highly correlated with APACHE II score [25] . In this study, we noticed that B10 and CD19 
hi cells might be a practical way to improve the early assessment of AP severity.
MATERIALS AND METHODS
Subjects
The study group comprised 63 patients with AP at Zhejiang's Province People's Hospital and 21 agematched healthy individuals. AP was diagnosed according to the presence of typical symptoms, such as abdominal pain, and more than three times the normal levels of serum amylase and lipase. All patients fulfilled the criteria for AP and were retrospectively categorized into MAP (n = 46) or SAP (n = 17) according to the Atlanta classification [39] . The characteristics of the patients are shown in Table  1 . Patients who were admitted later than 24 h from the onset of pain due to AP were excluded. Furthermore, patients with chronic pancreatitis, chronic liver diseases (cirrhosis or viral hepatitis), neoplasms of any origin and those treated with immunosuppressants were excluded. Blood samples were immediately obtained from each patient after admission and also on the third and seventh days. All patients received supportive management using intravenous fluid without oral alimentation. Parenteral antibiotics were prescribed for prevention of infection in patients with SAP. An echo-guided or CT-guided aspiration for Gram stain and bacterial culture was performed when infected necrosis or pancreatic abscesses were suspected. Percutaneous drainage or surgical management was performed if infected necrosis or pancreatic abscess was present. All patients were observed until they died or were followed up at the outpatient clinic if they were discharged. None of the patients received drugs affecting immune function .
This study was approved by the Ethics Committee of the Zhejiang's Province People's Hospital. Informed consent was obtained from all individual participants included in the study.
Cell isolation
PBMCs were isolated from blood samples using a Ficoll-Hypaque density gradient centrifugation method. 
Flow cytometric analysis
With respect to the surface marker staining, fresh peripheral blood was tested using the following monoclonal antibodies: APC-CD3 (SK7), FITC-CD19 (J4.119), PerCP-CD27 (L128), PerCP-cy5.5-CD24 (ML5), PE-CD80 (MAB104), PerCP-cy5.5-CD80 (MAB104), PE-CD86 (HA5.2B7), PerCP-cy5.5-CD86 (HA5.2B7), PerCP-cy5.5-CD8 (SK1), PE-CD14 (RMO52), FITC-HLA-DR (Immu-357) and FITC-CD64 (22) . After the cells were incubated with the antibodies for 30 min at 4°C in the dark, they were lysed with NH 4 CL solution. Data acquisition and analysis were performed using BD FACSCanto II flow cytometry with FACSDiva software (BD Biosciences, San Diego, CA, USA). The fluorescence intensity of CD64 expression on neutrophils and lymphocytes was measured as the MFI as a linearized value of a log scale. CD64 index is calculated by the ratio of the MFI of the granulocytes to that of the lymphocytes.
For the detection of T helper-secreted intracellular cytokines, peripheral blood mononuclear cells (PBMCs, 2 × 10 6 cells / mL) were stimulated with phorbol 12-myristate 13-acetate (PMA) (50 ng/mL, Sigma-Aldrich) plus ionomycin (1 mg/mL, Sigma-Aldrich) for 5 hours in the presence of monensin. After membrane staining for CD3 and CD8, the cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences, San Diego, CA, USA ) and were stained with PE-conjugated IL-17F (O79-289) and FITC-conjugated IFN-γ (B27). CD3 +
CD8
-cells, but not CD3 + CD4
+ cells, were defined as T helper cells, due to the downregulation of surface CD4 after stimulation with PMA and ionomycin.
Intracellular IL-10 analysis was performed as previously described [40] . PBMCs were resuspended (2 × 10 6 cells/mL) in RPMI1640 medium in the presence www.oncotarget.com of CpG (ODN 2006, 10 mg/mL; InvivoGen, San Diego, CA) and CD40 ligand (CD40L, 1 mg/mL; BD Biosciences); PMA (50 ng/mL, sigma), ionomycin (1 mg/ mL, sigma), and brefeldin A (5 mg/mL, BioLegend) were added for the last 5 hours of incubation. After membrane staining for CD3 and CD19, the cells were fixed and permeabilized using a Cytofix/Cytoperm kit and stained with a PE-conjugated IL-10 (JES5-19F1).
Cytokine immunoassays
The serum levels of IL-6, IL-10, IL-17, IFN-γ and TNF-α were determined using BD TM Cytometric Bead Array Human Th1 / Th2 / Th17 kits (BD Bioscience, San Diego, CA, USA). The minimum detectable levels for IL-6, IL-10, IL-17, IFN-γ and TNF-α were 2.4, 4.5, 7.6, 3.7 and 3.8 pg/mL, respectively. TGF-β levels were measured by enzyme-linked immunosorbent assay according to the manufacturer's instructions. All measurements were obtained in duplicate and according to the protocols provided by the manufacturers. ) in complete RPMI 1640, L-glutamine, and NaHCO3 supplemented with 10% FCS and penicillin /streptomycin (100 U/mL) in 96-well U-bottom plates in the presence of medium for 72 h, and with PIB (PMA + ionomycin+ brefeldin A) added in the last 5 h as described elsewhere. Cells were then surface-stained CD14, permeabilized, stained intracellularly for TNF-α and analyzed by flow cytometry.
Statistical analysis
Statistical analyses were performed by Student's t-test for the comparison of sample means between two groups or by one-way analysis of variance for comparisons of more than two groups. The Pearson product-moment correlation coefficient was used to examine the relationship between two continuous variables. The Wilcoxon matched paired rank test was used for matched paired samples. P values < 0.05 were considered to be statistically significant. The data were shown as the median (range) unless otherwise indicated. All analyses were performed using the Statistical Package for the Social Sciences statistical software for Windows, version 11.5 (SPSS Inc., Chicago, IL, USA).
Clinical assessment
Written informed consent was obtained from all the enrolled patients and healthy individuals.
